MapLight completes enrollment in schizophrenia and autism Phase 2 trials; results expected by mid-August 2026

MapLight Therapeutics has completed enrollment in its Phase 2 ZEPHYR trial for schizophrenia and the final patient visit in its Phase 2 IRIS trial for autism spectrum disorder. These trials evaluate the efficacy and safety of ML-007C-MA for schizophrenia and ML-004 for autism. The company expects topline results from both trials by mid-August 2026, marking a key milestone in developing new treatments for these central nervous system disorders. Successful outcomes could address significant unmet medical needs in schizophrenia and autism.